(Fighting New Coronary Pneumonia) French pharmaceutical company Sanofi will assist in the production of Pfizer vaccines this year and plans to provide 100 million doses to the EU
China News Agency, Paris, January 27 (Reporter Li Yang) French pharmaceutical company Sanofi confirmed on the 27th that it will assist in the production of the new crown vaccine jointly developed by Pfizer and BioNTech. This year plans to provide 100 million doses to the EU.
Sanofi officially confirmed on the 27th that it has reached an agreement with the two companies to help produce Pfizer vaccine.
Sanofi will use its own production lines and related technologies to assist in the production of Pfizer vaccines. The total production dose this year is initially estimated to be 125 million doses. The first batch of vaccines will be delivered this summer.
Data map: In January and September local time, the COVID-19 vaccination center in the Cannes Film Palace in Cannes, France, began to open.
The picture shows medical staff vaccinating the new crown vaccine at the new crown vaccination center in the movie palace.
Sanofi CEO Hudson said that the company plans to provide 100 million doses of Pfizer vaccine to the EU this year to meet the huge demand for new crown vaccines in EU countries.
Pfizer said this month that it would reduce the number of vaccines provided to EU countries, which triggered dissatisfaction with the EU. France also urged Pfizer to deliver vaccines on time.
According to news from the French BFM TV station and other media, Sanofi’s assistance in the production of Pfizer vaccines at this stage will mainly focus on filling drugs and packaging. Negotiations on the production of vaccine active ingredients are still in progress. Sanofi needs to obtain necessary logistics support. And technology transfer.
Sanofi said that the company's own test vaccine is still under development and may not be available until the end of this year.
The immune response of the test vaccine to the elderly is insufficient and the launch has to be postponed.
Hudson said that due to the postponement of Sanofi's vaccine, the company is now discussing ways to provide help in the fight against the epidemic.
Sanofi France's President Bogillo said that to return to normal life, as many people as possible must be vaccinated.
Therefore, united efforts are needed in vaccine production, and Sanofi has production capacity and expertise.
The French vaccination work is still facing a vaccine supply gap.
The French Ministry of Health revealed that France will receive only 4.6 million doses of AstraZeneca vaccine by the end of March, instead of the 16 million doses originally planned.
This means that France's future vaccination schedule will be affected.
(Finish)